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1  | INTRODUC TION
Alveolar echinococcosis (AE) is a very severe zoonotic helminthic 
disease, which is fatal if patients are not appropriately diagnosed 
and subsequently treated.1 AE is characterized by a chronically 
progressing hepatic damage caused by the continuous prolifera-
tion of the larval stage (metacestode) of Echinococcus multilocularis 
(E. multilocularis),2 that behaves like a slowly growing and metas-
tasizing liver cancer, thus progressively also invading other host 
tissues and organs such as lungs and brain, among others.3 For the 
treatment of AE, surgery is, so far, the only potentially curative 
option. Inoperable AE cases must undergo long- term chemother-
apy, often lifelong.4 Extensive animal experimentations and obser-
vations in human patients suffering from AE have demonstrated 
that ABZ and MBZ exhibit a parasitostatic rather than a parasit-
icidal effect.4,5 Therefore, recurrence rates after interruption of 
therapy are high. Beside the inconvenience of a daily and long- 
term drug administration, some patients experience side effects 
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Summary
The growth potential of the tumour- like Echinococcus multilocularis metacestode 
(causing alveolar echinococcosis, AE) is directly dependent upon the nature/function 
of the periparasitic adaptive host immune- mediated processes. PD- 1/PD- L1 path-
way (programmed cell death 1), which inhibits lymphocytic proliferation in tumour 
development, is over- expressed at the chronic stage of AE. We tested the impact of 
a PD- 1/PD- L1 pathway blockade on the outcome of both chronic AE (intraperitoneal 
metacestode	inoculation,	secondary	AE	and	SAE)	and	acute	AE	(peroral	egg	 infec-
tion, primary AE and PAE). To assess the parasite proliferation potential, we meas-
ured	parasite	mass	weight	for	SAE	and	liver	lesion	number	for	PAE.	In	both	models,	
the parasite load was significantly decreased in response to anti- PD- L1 antibody 
treatment.	In	SAE,	anti-	PDL1	administration	was	associated	with	increased	Th1	re-
sponse parameters and decreased Treg responses, while in PAE anti- PDL1 adminis-
tration was associated with fewer lesions in the liver and decreased Treg/Th2 
responses.	Our	findings	highly	suggested	that	a	PD-	1/PD-	L1	pathway	blockade	trig-
gered the host immune responses in favour of an immune- mediated control of E. mul-
tilocularis proliferation. Based on this, future studies that combine PD- 1/PD- L1 
blockade with a parasitostatic albendazole medication may yield in a putatively cura-
tive therapeutic approach to control alveolar echinococcosis.
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such as hepatotoxicity6,7 and drug interactions,8 thus alternative 
treatment options are required, especially when this could offer a 
curative prognosis.
Mechanistically, E. multilocularis metacestode infection is criti-
cally modulated by adaptive immune response of the host. In partic-
ular, an initial acute inflammatory Th1 response (putatively immune 
protective) is gradually converting into a mixed Th1/Th2 response 
during the chronic phase of AE,9,10 thus allowing parasite survival 
upon regulation via CD4+CD25+Foxp3+ T (Treg) cells and Th17 
cells,10 and thus finally leading to a lethal outcome of disease due to 
continuous long- term parasite proliferation and maturation.
In recent years, specific immunotherapies such as checkpoint 
blockade has become of great interest to researchers and clini-
cians, particularly in its promise to treat various forms of can-
cer,11 but also infectious diseases increasingly gained respective 
interest.12 With regard to helminth infection, it was shown that 
cestode Taenia crassiceps infections in mice induce macrophages 
alternatively activated with strong suppressive activity involving 
the PD- 1/PD- L1 pathway.13 Blockade of the PD- 1/PD- L1 pathway 
during infections with certain pathogens such as Toxoplasma re-
stored exhausted CD8+ T cell response,14 and promoted brain leu-
cocyte infiltration and diminishes cyst burden in another mouse 
infection model.15 It was also shown that blocking PD- L1 signal-
ling in Leishmania donovani- infected mice resulted in restoration of 
protective type 1 responses by both CD4+ and CD8+ T cells, which 
resulted in a significant decrease in the parasitic burden.16 With 
regard to echinococcosis, significantly higher levels of sPD-L1 in 
patients with cystic echinococcosis were observed compared with 
healthy controls, and elevated levels of Th2 cytokines in the sera 
of patients with CE.17 A recent study showed that upregulation 
of PD- 1 on CD4+CD25+T cells is associated with immunosuppres-
sion in liver of mice infected with E. multilocularis.18 Echinococcus 
multilocularis proliferation and some malignant tumours are both 
sharing similar features such as local immune evasion, induction of 
tolerance and disruption of T cell signalling,9,10,19 and T cell exhaus-
tion at late stage of infection.20 Monoclonal antibodies targeting 
PD- 1 or PD- L1 are in clinical use demonstrating high efficacy in 
lung, colon, head, neck and gastric cancers, in addition to renal cell 
carcinoma and melanoma.21-23
Based on these observations, the basic hypothesis of the present 
study was PD- 1/PD- L1 activation couple may represent a potential 
target to treat the tumour- like lesion development in AE. The major 
aims of the present study were as follows: (a) to determine the effi-
cacy of PD- 1/PD- L1 pathway blockade in the control of AE; and (b) 
to understand how it is acting by observing what happens in normal 
mice and in treated mice, and it is related adaptive (CD4+ T cell) and 
innate immune responses (DC, NK and NK T cell). To address these 
questions, we made use of two different mouse infection models, 
namely (a) intraperitoneal (i.p.) metacestode inoculation (secondary 
AE,	SAE),	representing	a	chronic	and	rather	advanced,	but	not	final	
stage of infection; and (b) peroral infection with parasite eggs (pri-
mary AE, PAE), representing the natural human infection mode (early 
or acute stage of infection at 2 weeks post infection (p.i.)).
2  | MATERIAL S AND METHODS
2.1 | Ethics statement
The animal studies were performed in strict accordance with the 
recommendations	of	the	Swiss	Guidelines	for	the	Care	and	Use	of	
Laboratory Animals. The protocol was approved by the governmen-
tal Commission for Animal Experimentation of the Canton of Bern 
(approval no. BE112/14 and BE112/17).
2.2 | Mice
Female 8- week- old wild- type C57/BL6 mice were purchased from 
Charles	River	GmbH	 (Sulzfeld,	Germany).	All	animals	were	housed	
under	 specific	 pathogen-	free	 (SPF)	 conditions	 according	 to	 rec-
ommendations of the Federation of European Laboratory Animal 
Science	Association	 (FELASA),	and	additionally	monitored	by	daily	
inspection, including the assessment of the appearance of health 
status, putative weight loss or gain during the whole course of the 
experiment. All experiments with animals were performed within a 
laminar flow safety enclosure.
2.3 | Experimental design, infection and PD- 
L1 blocking
2.3.1 | Experiment 1. PD- 1/PD- L1 pathway 
blockade against secondary AE
Parasite and intraperitoneal infection of mice
Intraperitoneal infection with E. multilocularis metacestodes was 
performed as previously described.24 Briefly, E. multilocularis (H95) 
was isolated and maintained by serial passages (vegetative transfer) 
in C57BL/6 mice as previously described.24 In order to prepare the 
infection material for mice, metacestode tissue was obtained from 
previously infected mice by aseptic removal from the peritoneal 
cavity. After grinding the tissue through a sterile 50 μm sieve, ap-
proximately 100 freshly prepared vesicular cysts were suspended 
in 100 μL	 sterile	 PBS	 (Gibco,	 Basel,	 Switzerland)	 and	 intraperito-
neally injected. Each experimental group included six animals unless 
otherwise stated. Control mice received 100 μL	of	sterile	PBS	only.	
Upon	end	of	experiments,	mice	were	sacrificed	by	CO2- euthanasia 
at 4 weeks post infection (corresponding to middle stage of chronic 
infection). Parasite tissues were dissected and, if present, fat and 
connective tissues were carefully removed for subsequent determi-
nation of the parasite mass.
PD- L1 blocking
All mice belonging to the PD- L1 blocking group (AE αPD- L1) re-
ceived 200 μg of anti- PD- L1 MAb i.p. (BioXcell, clone 10F.9G2, West 
Lebanon,	NH,	USA)	dissolved	in	100	μL	PBS	at	1	day	before	infection	
and maintained for 4 weeks, with a subsequent frequency of one 
injection/mouse every 4 days.25 All mice were daily monitored for 
survival and morbidity.
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2.3.2 | Experiment 2. PD- 1/PD- L1 pathway 
blockade against PAE
Parasite and oral infection of mice
Echinococcus multilocularis eggs were isolated from a naturally 
E. multilocularis-	infected	dog	euthanized	at	 the	Small	Animal	Clinic	
of the Vetsuisse Faculty due to a non- infectious health problem, 
infection was detected upon routine necropsy investigation by pa-
thologists.26,27 In order to prepare the infection material for mice, 
the dog intestine was removed under appropriate safety precautions 
and cut into four pieces. After opening the dog intestine, the worm- 
containing mucus sections were scraped out, put into petri dishes 
containing	sterile	water.	Subsequently,	the	mucosal	suspension	was	
serially filtered through a 500 μmØ and then 250 μmØ metal sieve, 
by concurrently disrupting the worms with an inversed 2 mL sy-
ringe top. This suspension was further filtered through a 105 μmØ 
nylon sieve. The eggs were then washed by repeated sedimentation 
(1 × g, 30 minutes, room temperature) in sterile water containing 1% 
penicillin/streptomycin and stored in the same solution at 4°C. For 
primary infection of mice, 8- to 10- week- old female animals were 
receiving approximately 400 eggs suspended in 100 μL sterile water, 
upon use of a blunt- ended feeding tube. Each experimental group 
included six animals unless otherwise stated. Control mice (mock- 
infection) received 100 μL water only. All mice (treated and mock- 
treated,	 see	below)	were	 sacrificed	by	CO2- euthanasia at 2 weeks 
post infection (corresponding to the early, acute stage of infection). 
The number of liver lesions was then macroscopically assessed as 
described elsewhere.28
PD- L1 blocking
All mice belonging to the PD- L1 blocking group (AE αPD- L1) re-
ceived 200 μg of anti- PD- L1 MAb i.p. (BioXcell, clone 10F.9G2) dis-
solved in 100 μL	PBS	at	1	day	before	 infection	and	maintained	for	
2 weeks, with a subsequent frequency of one injection/mouse every 
4 days.25 All mice were daily monitored for survival and morbidity.
2.4 | Total RNA extraction and qRT- PCR
Total RNA was isolated from spleens using the Qiagen RNeasy MiniKit 
according to the manufacturer’s instructions. The quality of the iso-
lated RNA was determined with a NanoDrop ND 1000 (NanoDrop 
Technologies,	 Wilmington,	 DE,	 USA)	 and	 a	 Bioanalyzer	 2100	
(Agilent,	Palo	Alto,	CA,	USA).	Only	samples	with	a	260-	nm:280-	nm	
ratio	between	1.9	and	2.1	and	a	28S:18S	ratio	within	1.5	to	2	were	
further	 processed.	 cDNA	 was	 synthesized	 using	 the	 Omniscript	
Reverse	 Transcription	 kit	 (Qiagen,	 Hilden,	 Germany).	 SYBR-	Green	
Mix- based qRT- PCR was carried out on a Rotor- Gene 6000 QPCR 
detection	system	(Corbett,	Foster	City,	CA,	USA)	with	the	FastStart	
Essential	DNA	Green	Master	 (Roche,	Basel,	 Switzerland)	 following	
the manufacturer’s instructions. PCR cycling was performed in tripli-
cates in final volumes of 20 μL containing 2 μL cDNA and 10 pmol/L 
of each primer (cycle scheme: initial denaturation at 95°C to 15 min-
utes, 45 cycles of 95°C to 15 seconds, 55°C to 30 seconds and 72°C 
to 30 seconds). Fluorescence was measured in every cycle, and a 
melting curve was analyzed after the PCR by increasing the tempera-
ture from 55 to 95°C in 0.5°C increments. The primers used were 
described earlier,29 and mRNA levels of different cytokines were 
quantified relative to the mRNA level of housekeeping gene β-actin.
2.5 | Cell preparation and flow cytometry
Spleen	cells	 from	naïve	 (control)	and	E. multilocularis- infected mice 
were collected by splenic grinding, each step with 5 mL RPMI- 1640. 
Cells were subsequently washed twice with and then resuspended 
in RPMI- 1640 (Gibco) for cell staining.
Aliquots of 106 cells/100 μL of staining buffer per well were in-
cubated each with 1 μg of purified anti- CD16/CD32 for 20 minutes 
in the dark, in order to block non- specific binding of antibodies to 
the FcγIII and FcγII	 receptors.	Subsequently,	 these	cells	were	sep-
arately stained with the following surface markers for 15 minutes 
with 1 μg of primary antibodies: PE- labelled CD3, PE- Cy5- labelled 
NK1.1 and APC- labelled anti- CD4. All antibodies were from eBio-
science	 (San	 Diego,	 CA,	 USA).	 For	 intracellular	 staining,	 spleen	
cells were first incubated with Inside Fix (Miltenyi Biotec, Bergisch 
Gladbach, Germany) for 20 minutes at room temperature and subse-
quently stained with PE- labelled anti- Foxp3, anti- IL- 10, anti- IL- 4 and 
anti- IFN- γ (eBioscience) in Inside Perm (Miltenyi Biotec) for 15 min-
utes in the dark. Corresponding fluorochrome- labelled isotype con-
trol antibodies were used for staining controls. Cells resuspended 
in 300 μL of buffer (0.15 mol/L NaCl, 1 mmol/L NaH2PO4 H2O,	
10 mmol/L Na2HPO4 2H2O	and	3	mmol/L	NaN3) were analysed in a 
flow cytometer (Becton Dickinson, Heidelberg, Germany) using the 
corresponding	CELL	QUEST	software.
2.6 | Statistical analyses
All	 data	 were	 analysed	 by	 SPSS	 17.0.	 The	 results	 are	 presented	
as	 means	±	SD.	 Normality	 of	 data	 was	 assessed	 by	 D’Agostino	 &	
Pearson	and	Shapiro-	Wilk	 test.	For	normally	distributed	groups	of	
data,	one-	way	ANOVA	followed	by	Bonferroni’s	post-	test	was	used	
to	 compare	 the	differences	between	groups.	 Significance	was	de-
fined as P < 0.05 for all tests, except those subsequently corrected 
by Bonferroni.
3  | RESULTS
3.1 | Part I: PD- 1/PD- L1 pathway plays a critical 
role in the overall infection control against secondary 
AE (intraperitoneal infection mode leading to chronic 
stage of AE)
3.1.1 | Significantly decreased parasite load in SAE 
mice with PD- 1/PD- L1 pathway blockade
Experiment 1 focused on the potential role of PD- 1/PD- L1 ligation in 
the immunological fight against secondary AE. Abrogation of PD- 1/
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PD- L1 pathway was obtained by anti- PD- L1 MAb administration 
(intraperitoneal injection, 200 μg/mouse/injection), initiated 1 day 
before infection and subsequently maintained for 4 weeks (with 1 
application/4 d). Parasite load was significantly reduced in response 
to	anti-	PD-	L1	MAb	(0.1	±	0.06	g)	in	SAE	mice	in	comparison	with	PBS	
- treated infected control animals (0.2 ± 0.07 g) (Figure 1A, P < 0.05).
3.1.2 | Increased Th1 and decreased Treg immune 
response in SAE mice treated with PD- 1/PD- L1 
pathway blockade
By using qRT- PCR, a significant increase of gene expression levels 
for IL- 2, IL- 12 and IFN- γ	was	observed	in	the	spleen	from	SAE-	WT	
mice treated with anti- PD- L1 MAb, when compared to the untreated 
infected	SAE-	WT	mice	(Figure	1B-	D;	for	all	P < 0.006). IL- 17A mRNA 
levels	showed	no	significant	difference	in	the	spleen	from	SAE-	WT	
mice treated with anti- PD- L1 MAb, when compared to the infected 
SAE-	WT	mice	 and	 to	 the	non-	infected	 controls	 (Figure	1E).	 Foxp3	
gene expression level was significantly decreased in the spleen from 
SAE-	WT	mice	treated	with	anti-	PD-	L1	MAb,	when	compared	to	the	
SAE-	WT	mice	(Figure	1F;	P < 0.006).
3.2 | Part II: Early blockade of PD- 1/PD- L1 pathway 
is very critical in the overall infection control against 
primary AE (peroral infection mode leading to 
acute or early stage AE)
3.2.1 | Significantly lower liver lesion numbers in 
PAE mice upon PD- 1/PD- L1 pathway blockade
Experiment 2 focused on the potential role of PD- 1/PD- L1 ligation in 
the immunological fight against primary AE. Abrogation of PD- 1/PD- L1 
pathway was obtained by anti- PD- L1 MAb treatment (intraperitoneal 
injection, 200 μg/mouse/injection), initiated 1 day before infection 
and subsequently maintained for 2 weeks (with 1 application/4 d). In 
the natural (peroral) infection system, anti- PD- L1 MAb administration 
F IGURE  1 Parasite	load	and	Th1/Treg	responses	in	secondary	AE	(SAE)	mice	with	PD-	1/PD-	L1	pathway	blockade.	A,	Eight-	week-	old	
female wild- type C57/BL6 mice were infected intraperitoneally with Echinococcus multilocularis metacestode. Anti- PD- L1 MAb application 
with 200 μg/mouse/injection started 1 d before infection and was maintained for 4 wk (application every 4 d). Parasite weight was 
determined by wet weight measurement at 4 wk post secondary E. multilocularis infection and necropsy. Data represent individual mice from 
of	three	independent	experiments	of	a	total	of	six	mice	in	each	group.	Comparison	between	groups	was	performed	using	a	one-	way	ANOVA	
for statistical analysis. *P < 0.05. B, IL- 2; C, IL- 12; D, IFN- γ; E, IL- 17A; F, Foxp3 mRNA expression levels in the spleen of mice following 
secondary E. multilocularis	infection	(measured	by	qRT-	PCR).	Data	represent	mean	±	SD	of	a	total	of	six	mice	in	each	group.	Comparison	
between	groups	was	performed	using	a	one-	way	ANOVA	with	Bonferroni’s	multiple	comparison	post-	test	for	statistical	analysis.	*P < 0.006. 
Control:	non-	infected	wild-	type	mice;	SAE-	WT:	E. multilocularis	secondarily	infected	wild-	type	mice;	SAE-	αPD- L1: E. multilocularis 
secondarily infected wild- type mice treated with anti- PD- L1 MAb
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resulted in a significantly lower number of liver lesions, as compared to 
the infected non- treated group (PAE- WT; P < 0.05; Figure 2A).
3.2.2 | Decreased Treg immune response in PAE 
mice with PD- 1/PD- L1 pathway blockade
Peroral infection was associated with an increase of CD4+ Foxp3+ and 
CD4+ IL- 10+ cells in the spleen, when compared to the non- infected 
WT controls (Figure 2B- D; P < 0.008). There was a significant de-
crease of both CD4+ Foxp3+ and CD4+ IL- 10+ frequency in the spleen 
from PAE mice treated with anti- PD- L1 MAb, when compared to 
PAE- WT mice (Figure 2B- D; P < 0.008). qRT- PCR yielded for Foxp3 
and IL- 10 gene expression level of 2.0 AU (mean arbitrary units) and 
1.0 AU (mean) in the spleen of PAE- WT mice, while in PAE- WT mice 
treated with anti- PD- L1 MAb the mRNA expression levels were 0.7 
and 0.05 AU, respectively (Figure 2E).
3.2.3 | Decreased Th2 immune response in PAE 
mice with PD- 1/PD- L1 pathway blockade
A significant increase of CD4+ IL- 4+ frequency in the spleen was 
observed at 2 weeks post oral infection with E. multilocularis eggs 
F IGURE  2 Lesion numbers in the liver in primary AE (PAE) mice with PD- 1/PD- L1 pathway blockade, association with Foxp3- and IL- 
10- levels. A, Eight- week- old female wild- type C57/BL6 mice were infected perorally with Echinococcus multilocularis eggs. Anti- PD- L1 MAb 
application with 200 μg/mouse/injection started 1 d before infection and was maintained for 2 wk (every 4 d). Lesion number in the liver 
from PAE- WT mice with/without anti- PD- L1 MAb treatment mice at 2 wk post primary infection. Data represent individual mice of three 
independent	experiments	of	a	total	of	six	mice	in	each	group.	Comparison	between	groups	was	performed	using	a	one-	way	ANOVA	for	
statistical analysis. *P < 0.05. B, Frequency of Foxp3+ cells within CD4+ T cells in spleen cells from PAE- WT mice with/without anti- PD- L1 
MAb treatment at 2 wk postinfection. C, Frequency of IL- 10+ cells within CD4+ T cells in spleen cells from PAE- WT mice with/without anti- 
PD- L1 MAb treatment at 2 wk postinfection. D, Representative images of Foxp3+ and IL- 10+ cells within CD4+ T cells in spleen cells from 
PAE- WT mice with/without anti- PD- L1 MAb treatment at 2 wk postinfection. E, Foxp3 and IL- 10 gene expression levels in spleen cells from 
PAE-	WT	mice	with/without	anti-	PD-	L1	MAb	treatment	at	2	wk	postinfection	(measured	by	qRT-	PCR).	Data	represent	mean	±	SD	of	three	
independent	experiments	of	a	total	of	six	mice	in	each	group.	Comparison	between	groups	was	performed	using	a	one-	way	ANOVA	with	
Bonferroni’s multiple comparison post- test for statistical analysis. *P < 0.008. Control: non- infected wild- type mice; PAE- WT: E. multilocularis 
primarily infected wild- type mice; PAE- αPD- L1: E. multilocularis primarily infected wild- type mice treated with anti- PD- L1 MAb
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(PAE mice), when compared to the non- infected WT controls 
(Figure 3A,B; P < 0.025). There was a significant decrease in CD4+ 
IL- 4+ frequency in the spleen from PAE mice treated with anti- PD- L1 
MAb, when compared to PAE- WT mice (Figure 3A,B; P < 0.025). 
However, there was no difference in CD4+ IFN- γ+ frequency in the 
spleen between PAE- WT mice with and without anti- PD- L1 MAb 
treatment (Figure 3C,D; P < 0.025). qRT- PCR showed that IL- 4 gene 
expression levels were at 3.0 ± 1.0 AU in AE- WT and at 1.0 ± 0.3 in 
the spleen from anti- PDL- 1- treated PAE mice (Figure 3E; P < 0.025). 
No difference for IFN- γ expression levels was observed in the spleen 
from PAE- WT mice treated with anti- PD- L1 MAb, when compared 
to untreated PAE- WT mice (Figure 3F; P < 0.025).
3.2.4 | Innate immune responses are activated 
in PAE mice but not altered with PD- 1/PD- L1 
pathway blockade
By flow cytometry, a significant increase of NK cell number in 
the spleen was observed in PAE mice compared to infection- 
free WT controls (Figure 4A- C; P < 0.025). No difference in NK 
T cell number in the spleen was found between the study groups 
(Figure 4A- C; P < 0.025). The NK cell or NK T cell numbers were 
similar in the spleen from PAE- WT mice treated with anti- PD- L1 
MAb and those PAE- WT and untreated WT animals (Figure 4A- C; 
P < 0.025).
F IGURE  3 Th2/Th1 immune responses in primary AE (PAE) mice with PD- 1/PD- L1 pathway blockade. A, Frequency of IL- 4+ cells 
within CD4+ T cells in spleen cells from PAE- WT mice with/without anti- PD- L1 MAb treatment at 2 wk postinfection. B, Representative 
images of IL- 4+ cells within CD4+ T cells in spleen cells from PAE- WT mice with/without anti- PD- L1 MAb treatment at 2 wk postinfection. 
C, Frequency of IFN- γ+ cells within CD4+ T cells in spleen cells from PAE- WT mice with/without anti- PD- L1 MAb treatment at 2 wk 
postinfection. D, Representative images of IFN- γ+ cells within CD4+ T cells in spleen cells from PAE- WT mice with/without anti- PD- L1 MAb 
treatment at 2 wk postinfection. E, IL- 4 gene expression levels in spleen cells from PAE- WT mice with/without anti- PD- L1 MAb treatment 
at 2 wk postinfection (measured by qRT- PCR). F, IFN- γ gene expression levels in spleen cells from PAE- WT mice with/without anti- PD- L1 
MAb treatment at 2 wk postinfection (measured by qRT- PCR). Anti- PD- L1 MAb application with 200 μg/mouse/injection started 1 d before 
infection	and	was	maintained	for	2	wk	(every	4	d).	Data	represent	mean	±	SD	of	three	independent	experiments	of	a	total	of	six	mice	in	each	
group.	Comparison	between	groups	was	performed	using	a	one-	way	ANOVA	for	statistical	analysis.	*P < 0.025. Control: non- infected wild- 
type mice; PAE- WT: Echinococcus multilocularis primarily infected wild- type mice; PAE- αPD- L1: E. multilocularis primarily infected wild- type 
mice treated with anti- PD- L1 MAb
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4  | DISCUSSION
The presence of PD- 1 and PD- L1 has a major role in the inhibition 
of effector T cell function.30 Clinical studies have indicated that an-
tibodies blocking PD- 1 and PD- L1 have a reliable effect on many 
advanced malignancies.31,32 PD- 1 and PD- L1 targeting is an effi-
cient way to maintain the function of effector T cells. Monoclonal 
antibodies (MAbs) are a class of drugs called checkpoint inhibitors 
that inhibit the interaction of PD- 1 and PD- L1 and overcome the dis-
advantages of conventional anticancer therapy. In vitro and in vivo 
studies that were done by Lussier et al33 showed that blocking PD- 1 
using an antibody could partially increase T cell function. MAbs- 
based immunotherapy can, when compared to chemotherapy, sig-
nificantly work under reduced toxicity within usually tolerable limits, 
while being able to shrink solid tumours, suppress advanced tumours 
and metastasis, and overall improve patient survival.34,35 In the 
present study, it was shown that (a) a significantly decreased para-
site load in mice following intraperitoneal infection and concomitant 
PD- 1/PD- L1 pathway blockade, which associated with an increased 
Th1/Th17 and decreased Treg immune response; (b) significantly 
fewer liver lesions in oral- infected AE mice and concomitant PD- 1/
PD- L1 pathway blockade, which associated with a decreased Treg/
Th2 immune response; and (c) PD- 1/PD- L1 pathway appears thus 
as a potential immunotherapeutical target against both primary and 
secondary AE.
Tregs, which over- express a subset of regulatory cytokine genes 
including those coding for IL- 10 and TGF- β, play an important role 
in promoting immune tolerance in a number of parasitic disease 
models.36 CD4+CD25+ Tregs were upregulated in PECs from wild- 
type E. multilocularis-	infected	 mice	 (i.p.	 infection,	 SAE),37 when 
compared to non- infected littermates. With inducible depletion of 
Foxp3+ Tregs, the metacestode growth yielded a significantly lower 
F IGURE  4 NK/NKT cells in the spleen cells from primary AE (PAE) mice with PD- 1/PD- L1 pathway blockade. A, Frequency of NK cells 
in spleen cells from PAE- WT mice with/without anti- PD- L1 MAb treatment at 2 wk postinfection. B, Frequency of NK T cells in spleen cells 
from PAE- WT mice with/without anti- PD- L1 MAb treatment at 2 wk postinfection. C, Representative images of NK/NKT cells in spleen 
cells from PAE- WT mice with/without anti- PD- L1 MAb treatment at 2 wk postinfection. Anti- PD- L1 MAb application with 200 μg/mouse/
injection	started	1	d	before	infection	and	was	maintained	for	2	wk	(every	4	d).	Data	represent	mean	±	SD	of	three	independent	experiments	
of	a	total	of	six	mice	in	each	group.	Comparison	between	groups	was	performed	using	a	one-	way	ANOVA	for	statistical	analysis.	*P < 0.025. 
Control: non- infected wild- type mice; PAE- WT: Echinococcus multilocularis primarily infected wild- type mice; PAE- αPD- L1: E. multilocularis 
primarily infected wild- type mice treated with anti- PD- L1 MAb
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parasite	load	(i.p.	infection,	SAE)	not	only	when	Foxp3+ Tregs were 
depleted preventively before E. multilocularis infection,38 but also 
when they were depleted therapeutically when the infection was 
already established (oral infection, PAE).39 The significantly smaller 
average lesion size in the liver due to Foxp3+ Tregs depletion in PAE 
was associated with a higher Th1 immune response, a lower IL- 10 
production and upregulation of APC activation.39 The late infection 
of	both	SAE	and	PAE	was	characterized	by	a	strong	Foxp3	expres-
sion and weak expression of most mediators, suggesting that their 
production is suppressed by Tregs.39 Understanding how Tregs reg-
ulates the immune process in AE could thus help finding new immu-
notherapeutical targets, that is, PD- 1/PD- L1 ligation. In the present 
study, in both infection mouse models, Treg immune response 
was decreased upon anti- PD- L1 MAb application. Tregs (CD4+ 
Foxp3+) create a highly immunosuppressive tumour environment 
through maintenance of the expression of PD- 1 on its surface.40 
In the presence of CD3 and TGF- β, the PD- 1 receptor of Treg cells 
was found to increase the de novo transformation of naive CD4+ 
T cells to Treg cells, thus attenuating immune effector responses. 
This conversion increases Treg expression and immune suppressive 
function of CD4+ T cell through inhibition of mammalian target of 
rapamycin	(mTOR)-	Akt	signalling	cascade.41 Thus, the presence of 
PD- 1 expression not only suppresses effector T cell function but 
also increases the conversion of the immunosuppressive Treg cell 
population.
From the major findings accumulated in the last two decades, in 
E. multilocularis metacestode infection, an initial acute inflammatory 
Th1 response is gradually converting into a mixed Th1/Th2 response 
during the chronic phase of AE.9,10 This still relatively simple Th1/
Th2 paradigm has been continually revised, and alternative T cell lin-
eages have been proposed to fine- tune the host immune response. 
PD- 1 blockade resulted in an increased Th1 effector response,33 and 
increased levels of IL- 2, IFN- γ and TNF- α after PHA or Candida stim-
ulation of blood cells from both healthy controls and HIV- infected 
subjects were demonstrated.42 Anti- PD- L1 MAb treatment also 
led to an increased Th1 response and reduced Th2 response during 
echinococcosis. This might suggest that PD- 1/PD- L1 pathway block-
ade could possibly promote a curative immune response against AE 
through tipping the Th1/Th2 balance and through inhibition of Treg 
cells. Future studies will thus have to address the question if long- 
term modulating of the PD- 1/PD- L1 pathway may contribute to cure 
AE immunologically.
Natural killer (NK) and NK T cells are an innate- like lymphocyte 
population. They express markers associated with both T cells and 
NK cells. NK/NKT cells can regulate diverse immune responses 
and produce large quantities of cytokines following activation. A 
lower NK cell cytotoxicity was found in PBMC of patients with 
AE in comparison with patients with non- parasitic biliary dis-
ease,43 and the low number of NK cells was associated with the 
lack of NKG2D expression on CD8+ T cells in liver sections of pa-
tients with AE.44 A most recent study showed that exposure to 
E. multilocularis- vesicle fluid had a significant bearing on activation 
and proliferation of NK cells in human PBMC, suggesting that NK 
cells may play an important role in the immune response of the 
host against E. multilocularis.45 Albeit widely studied during viral, 
bacterial and protozoan parasite infections, however, the role of 
NK T cells during metazoan parasite infections especially E. multi-
locularis infection remains still largely unexplored. In the present 
study, a significant increase of NK cell number but no difference 
in NK T cell number was observed in PAE mice compared to 
infection- free WT controls, suggesting NK cells play an important 
role against acute AE. However, there was no difference in NK cell 
or NK T cell numbers treated with or without anti- PD- L1 MAb. 
The mechanism how PD1/PD- L1 ligation regulates NK/NK T cells 
needs to be further studied.
Overall,	 the	 present	 results	 highly	 suggest	 that	 a	 PD-	1/PD-	L1	
pathway blockade is very promising in contributing and immuno-
therapeutical support to treat and control larval E. multilocularis in-
fection. An anticipated understanding of the mechanism by which 
PD- 1/PD- L1 pathway blockade regulates the immune process in 
AE may also help to find new alternative immunotherapeutic tar-
gets. Up to now, IFN- γ and IL- 12 are the only cytokines that have 
been experimentally tested for their therapeutic effects and were 
shown to be partially46 or totally47 effective for controlling parasite 
growth; IFNα- 2α was able to effectively suppress AE occurrence via 
an enhanced Th1 and a lower Th2 immunity in the mouse model,48 
and IFNα- 2α administration was reported to reduce AE lesion size in 
one patient co- infected with HCV.49 However, it was never tested 
as therapeutic agents whether this was applicable to larger numbers 
of human AE patients. Alveolar echinococcosis still remains a severe 
life- threatening disease without a fully curative therapy, and new 
treatment options are urgently needed.1
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